MetaVia (NASDAQ:MTVA) Stock Rating Upgraded by Wall Street Zen

MetaVia (NASDAQ:MTVA) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also issued reports about the stock. HC Wainwright increased their target price on shares of MetaVia from $12.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $36.50.

MetaVia Stock Performance

Shares of MTVA stock opened at $3.11 on Friday. The company has a market cap of $6.84 million, a P/E ratio of -0.37 and a beta of 0.27. The stock has a 50 day simple moving average of $8.19 and a two-hundred day simple moving average of $8.69. MetaVia has a fifty-two week low of $2.95 and a fifty-two week high of $23.54.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.86) by $1.32. On average, research analysts predict that MetaVia will post -3.9 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC grew its holdings in shares of MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,386 shares of the company’s stock after buying an additional 18,506 shares during the quarter. SG Americas Securities LLC owned 0.25% of MetaVia worth $57,000 at the end of the most recent reporting period. 1.37% of the stock is currently owned by institutional investors.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.